Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
Immune checkpoint blockade represents a major breakthrough in advanced non-small cell lung cancer (NSCLC) therapy. However, success is limited to a subset of patients and there is a critical need to identify robust biomarkers associated with clinical response. In this study, we assessed whether pre-...
Main Authors: | Selene Ottonello, Carlo Genova, Irene Cossu, Vincenzo Fontana, Erika Rijavec, Giovanni Rossi, Federica Biello, Maria Giovanna Dal Bello, Marco Tagliamento, Angela Alama, Simona Coco, Simona Boccardo, Irene Vanni, Guido Ferlazzo, Lorenzo Moretta, Francesco Grossi, Maria Cristina Mingari, Paolo Carrega, Gabriella Pietra |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-02-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00125/full |
Similar Items
-
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab
by: Jessica Cusato, et al.
Published: (2019-01-01) -
Symptomatic Carotid Atherosclerotic Plaques Are Associated With Increased Infiltration of Natural Killer (NK) Cells and Higher Serum Levels of NK Activating Receptor Ligands
by: Irene Bonaccorsi, et al.
Published: (2019-07-01) -
Targeted Therapies: Friends or Foes for Patient's NK Cell-Mediated Tumor Immune-Surveillance?
by: Laura Damele, et al.
Published: (2020-03-01) -
Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy
by: Melania Grottoli, et al.
Published: (2022-10-01) -
CTLA-4 expressed by human dendritic cells modulates thei cytokine secretion and induction of T cell proliferation
by: S. Laurent, et al.
Published: (2011-01-01)